AstraZeneca

Incorporated in 1989, Otsuka America Pharmaceutical is a health care company that commercializes its products throughout North America. It offers products under the ABILIFY Tablets1 and PLETAL Tablets2 brands. The company works in collaboration with Bristol-Myers Squibb, which co-develops and co-promotes ABILIFY. Otsuka America Pharmaceutical has also merged with Meretek Diagnostics to form the Meretek Diagnostics Group under the Medical Device Division of OAPI. It focuses on neuroscience, cardiovascular, oncologic and gastrointestinal therapeutic treatments. The company operates Otsuka Maryland Research Institute, which was established as a wholly-owned subsidiary of OAPI to research and develop a variety of health care products. Otsuka America Pharmaceutical is a part of Otsuka Pharmaceutical Group.

Emergent BioSolutions is a biopharmaceutical company headquartered in Rockville, Md. It develops, manufactures and commercializes a range of immunobiotics, including vaccines and therapeutics. Its BioThrax vaccine, approved by the Food and Drug Administration, is used for the prevention of anthrax infection. The company s commercial business focuses on immunobiotics that are used against infectious diseases and other medical conditions. Its commercial portfolio includes vaccines for hepatitis, meningitis and typhoid disorders. Emergent BioSolutions operates various offices in Singapore, Germany and the United Kingdom. It also maintains a network of third-party marketing representatives in the Middle East, Turkey, India, Australia and several Scandinavian countries in Europe.

AstraZeneca is a global pharmaceutical company that is dedicated to transforming the future of healthcare through the power of science. With a focus on precision medicine and transformative science, they develop innovative therapies in areas such as oncology, cardiovascular health, respiratory diseases, and immunology. Their research approach aims to target the underlying molecular causes of diseases, leading to more accurate patient classification and the discovery of new biomarkers and treatment targets. Committed to sustainability and access to healthcare, AstraZeneca also prioritizes environmental protection, ethics, and transparency. They actively engage in partnerships and alliances to support their communities and champion inclusion and diversity. With a robust pipeline of 167 projects and a global network of science centers, AstraZeneca is at the forefront of scientific advancements in the pharmaceutical industry.Generated from the website